UCLA Health

Running trials

• Recruiting

  A Study of DS-3939a in Participants With Solid Tumors

  NCT07739966· Phase 1/2· Daiichi Sankyo· Source

• Recruiting

  Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  NCT07700979· Phase 3· Akeso· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Gaucher Disease Gene Therapy Trial With FLT201

  NCT07223944· Phase 3· Spur Therapeutics· Source

• Active, not recruiting

  A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

  NCT06985147· Phase 2· Disc Medicine, Inc· Source

• Recruiting

  A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

  NCT06858397· Phase 1/2· GC Biopharma Corp· Source

• Recruiting

  A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

  NCT06827613· Phase 1/2· Marengo Therapeutics, Inc.· Source

• Active, not recruiting

  A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

  NCT06848231· Phase 2· Dasher Neuroscience Inc.· Source

• Recruiting

  A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  NCT06072781· Phase 3· Verastem, Inc.· Source

• Recruiting

  Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

  NCT04875702· Phase 4· Massachusetts General Hospital· Source

• Recruiting

  A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

  NCT05970497· Phase 1/2· Krystal Biotech, Inc.· Source

• Recruiting

  The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

  NCT05836987· Phase 3· Johns Hopkins University· Source

• Recruiting

  Treatment of Refractory Infantile Spasms With Fenfluramine

  NCT04289467· Phase 2· Children's Hospital of Orange County· Source

• Recruiting

  Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

  NCT05419726· University of California, Los Angeles· Source

• Active, not recruiting

  The DISCOVER INOCA Prospective Multi-center Registry

  NCT05288361· Yale University· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

  NCT05031780· Phase 2/3· Agios Pharmaceuticals, Inc.· Source

• Recruiting

  Pancreatic Cancer Early Detection Consortium

  NCT04970056· Arbor Research Collaborative for Health· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Atrial fibrillation1 recruiting
• Fabry disease1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Gaucher disease1 recruiting
• Gout1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Completed

  Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

  NCT05641896· Phase 2· SOFIE· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

  NCT05001737· Phase 3· Swedish Orphan Biovitrum· Source

• Completed

  Allergic Disease Onset Prevention Study

  NCT05003804· Phase 1/2· Siolta Therapeutics, Inc.· Source

• Terminated

  GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

  NCT04100135· W.L.Gore & Associates· Source

• Completed

  DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

  NCT04014075· Phase 2· Daiichi Sankyo· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Metastatic breast cancer13 works · 1 trial